Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.67 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.67 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.67 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.67 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.67 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.67 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.67 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.67 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.67 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.67 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.67 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.67 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.67 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.67 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8813092 | 0.94 | SMN1; SMN2 (0.60) | SMN1; SMN2HDAC3MAPK1ADRA1AHDAC4 | |
| SCHEMBL414487 | 0.94 | MAPT (0.66) | SMN1; SMN2HDAC3MAPK1ADRA1AHDAC4 | |
| Sulfuric Acid SCHEMBL8364343 | 0.93 | SMN1; SMN2 (0.58) | SMN1; SMN2HDAC3MAPK1ADRA1AHDAC4 | |
| SCHEMBL25293960 | 0.92 | MAPT (0.69) | SMN1; SMN2HDAC3MAPK1ADRA1AHDAC4 | |
| SCHEMBL9567562 | 0.92 | MAPT (0.69) | SMN1; SMN2HDAC3MAPK1ADRA1AHDAC4 | |
| SCHEMBL2489624 | 0.92 | MAPT (0.69) | SMN1; SMN2HDAC3MAPK1ADRA1AHDAC4 | |
| SCHEMBL29655693 | 0.92 | MAPT (0.69) | SMN1; SMN2HDAC3MAPK1ADRA1AHDAC4 | |
| SCHEMBL6208836 | 0.89 | SMN1; SMN2 (0.82) | SMN1; SMN2HDAC3MAPK1ADRA1AHDAC4 | |
| SCHEMBL193318 | 0.87 | FFAR1 (0.79) | FFAR1HTT | |
| SCHEMBL69789 | 0.87 | SMN1; SMN2 (0.78) | SMN1; SMN2HDAC3MAPK1ADRA1AHDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 234 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114713044-B | Method for improving pollution resistance of composite nanofiltration membrane | 浙江理工大学 | 2023-05-05 | — | — | CN | claimed |
| CN-114713044-A | Method for improving anti-pollution performance of composite nanofiltration membrane | 浙江理工大学 | 2022-07-08 | — | — | CN | claimed |
| CN-113683805-B | Preparation method of cross-linked imidazole functionalized polyether sulphone anion exchange membrane containing benzimidazole structure | 浙江工业大学 | 2022-06-21 | — | — | CN | claimed |
| CN-113683805-A | Preparation method of cross-linked imidazole functionalized polyether sulphone anion exchange membrane containing benzimidazole structure | 浙江工业大学 | 2021-11-23 | — | — | CN | claimed |
| WO-2016029146-A1 | SPECIFIC INHIBITORS OF METHIONYL-TRNA SYNTHETASE | UNIVERSITY OF WASHINGTON (US) | 2016-02-25 | — | — | WO | claimed |
| US-20070264241-A1 | Compounds for Enhanced Cancer Therapy | ZGENE A/S (DK) | 2007-11-15 | — | — | US | claimed |
| WO-2005079849-A2 | COMPOUNDS FOR ENHANCED CANCER THERAPY | ZGENE A/S (DK) | 2005-09-01 | — | — | WO | claimed |
| EP-0784604-B1 | PROCESS FOR THE PREPARATION OF (E)-2-FLUOROMETHYLENE-4-(4-FLUOROPHENYL) BUTAN-1-OL | HOECHST MARION ROUSSEL INC (US) | 1999-11-17 | — | — | EP | claimed |
| US-5883124-A | ADMINISTERING PHENYLACETIC ACID DERIVATIVE AND RETINOID TO TREAT TUMORS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1999-03-16 | — | — | US | claimed |
| US-5843994-A | Compositions and methods for treating and preventing pathologies including cancer | THE UNITED STATES OF AMERICA AS REPRESENETED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1998-12-01 | — | — | US | claimed |
| EP-0771196-A4 | EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 1997-09-03 | — | — | EP | claimed |
| US-5661179-A | ADMINISTERING; TREATS NEUROBLASTOMA, MYELODYSPLASIA, NON-SMALL CELL LUNG CANCER, PROSTATE CANCER, MELANOMA, BRAIN TUMOR, KAPOSI'S SARCOMA, LYMPHOMA, LEUKEMIA, BREAST AND LUNG CANCER, OSTEOSARCOMA AND FIBROSARCOMA | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1997-08-26 | — | — | US | claimed |
| US-5654333-A | THERAPY FOR ANEMIA, CANCER, AIDS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1997-08-05 | — | — | US | claimed |
| EP-0784604-A1 | PROCESSES FOR THE PREPARATION OF (E)-2-FLUOROMETHYLENE-4-(4-FLUOROPHENYL) BUTYLAMINE AND ALKALI METAL SALTS OF DIFORMYLAMIDE | HOECHST MARION ROUSSEL, INC. (US) | 1997-07-23 | — | — | EP | claimed |
| US-5635532-A | ADMINISTERING PHENYL OR NAPHTHYL ACETIC ACID DERIVATIVES | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1997-06-03 | — | — | US | claimed |
| US-5635533-A | ANTITUMOR AGENTS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1997-06-03 | — | — | US | claimed |
| EP-0771196-A1 | EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1997-05-07 | — | — | EP | claimed |
| US-5605930-A | ADMINISTERING PHENYLACETIC ACID AS AN INHIBITOR OF THE MEVALONATE PATHWAY | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1997-02-25 | — | — | US | claimed |
| WO-1996010003-A1 | PROCESSES FOR THE PREPARATION OF (E)-2-FLUOROMETHYLENE-4-(4-FLUOROPHENYL) BUTYLAMINE AND ALKALI METAL SALTS OF DIFORMYLAMIDE | HOECHST MARION ROUSSEL, INC. (US) | 1996-04-04 | — | — | WO | claimed |
| WO-1996007405-A1 | EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1996-03-14 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070264241-A1 | Compounds for Enhanced Cancer Therapy | TYMP, BAD, NUDT1 | SMN1; SMN2 372/4885HDAC3 2582/4885MAPK1 4409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.